Primus Pharmaceuticals
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Primus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Primus Pharmaceuticals: 15 sponsored US clinical trials, none currently recruiting.
Primus Pharmaceuticals sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 7 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sciatica Acute, with 1 trials.
Top-decile sponsor footprint
Primus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177
Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg
NCT06348303
Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition
NCT06382662
EpiCeram for Skin Protection in Healthcare Workers
NCT04793711
Vasculera in Participants With Lipedema
NCT05616962
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
NCT03179605
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
NCT02749799
Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon
NCT02683408
DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
NCT02527421
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
NCT02070965
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
NCT01947491
A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis
NCT01967069
Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee
NCT00435292
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study
NCT00303017
Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee
NCT00928837
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 3 |
| Phase 4 | 4 |
Therapeutic Areas
How the Primus Pharmaceuticals archive is shaped
15 indexed studies, none listed as recruiting (0% open); 11 completed (73%).
Phase mix: 7 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: Sciatica Acute (1 trial), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Primus Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Primus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Primus Pharmaceuticals page
15 registered trials is a research-attention snapshot, not an endorsement of Primus Pharmaceuticals or any single study.
- None of Primus Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Sciatica Acute is the condition Primus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sciatica Acute trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Primus Pharmaceuticals pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.